Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis

The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA). By corollary, the IL-12/23 inhibitor, Ustekinumab has been developed as an approved therapeutic for the skin and musculoskeletal syndrome of psoria...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental rheumatology 2015-09, Vol.33 (5 Suppl 93), p.S115-S118
Hauptverfasser:	Johnsson, Hanna J, McInnes, Iain B
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Arthritis, Psoriatic - diagnosis Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - immunology Biological Products - adverse effects Biological Products - therapeutic use Humans Inflammation Mediators - antagonists & inhibitors Inflammation Mediators - immunology Interleukin-12 - antagonists & inhibitors Interleukin-12 - immunology Interleukin-23 - antagonists & inhibitors Interleukin-23 - immunology Molecular Targeted Therapy Remission Induction Signal Transduction - drug effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA). By corollary, the IL-12/23 inhibitor, Ustekinumab has been developed as an approved therapeutic for the skin and musculoskeletal syndrome of psoriasis / PsA. This review describes briefly the role of IL-12 and IL-23 in the pathophysiology of psoriatic arthritis and evaluates trial data that support its clinical use in psoriasis and different manifestations of psoriatic arthritis. The next steps towards targeting this pathway also are discussed.
ISSN:	0392-856X